Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20010166&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates Kristinsson SY; Landgren O; Rajkumar VSCancer J 2009[Nov]; 15 (6): 473-8In the twenty-first century, melphalan-prednisone can no longer be regarded as the standard treatment of multiple myeloma patients not eligible for high-dose melphalan followed by autologous stem cell transplantation. The introduction of thalidomide, lenalidomide, and bortezomib has improved the arsenal of therapeutic options in multiple myeloma. Indeed, randomized studies have shown that melphalan-prednisone-thalidomide and melphalan-prednisone-bortezomib are superior to melphalan-prednisone alone. In addition, other combinations, including lenalidomide, are under study. In this review, we discuss the role of novel therapies in multiple myeloma in elderly multiple myeloma patients. Important aspects, such as toxicity and the role of prognostic factors, are also addressed.|Angiogenesis Inhibitors/administration & dosage[MESH]|Antineoplastic Agents, Hormonal/administration & dosage[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|Boronic Acids/administration & dosage[MESH]|Bortezomib[MESH]|Dexamethasone/administration & dosage[MESH]|Humans[MESH]|Lenalidomide[MESH]|Melphalan/administration & dosage[MESH]|Multiple Myeloma/*drug therapy[MESH]|Prednisone/administration & dosage[MESH]|Prognosis[MESH]|Pyrazines/administration & dosage[MESH]|Thalidomide/administration & dosage/analogs & derivatives[MESH] |
